Genexine, Inc. engages in research and development of novel immunotherapies for cancer and antibody therapies for rare diseases. Its pipeline of medicines is built upon its proprietary technologies, the hyFc and DNA vaccine platforms. The hyFc platform technology is used for development of long-acting protein drugs, maximizing the half-life of drugs in the human body through fusion with various drugs. The DNA vaccine platform inserts a genetic fragment involved in protein production into a vaccine, eliciting immune responses in the human body to fight viral infection and cancer cells. The company was founded by Young Chul Sung on June 8, 1999 and is headquartered in Seoul, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company